Last updated on March 2019

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Brief description of study

This is a study to evaluate whether macitentan is an effective and safe treatment for patients with heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease.

The primary objective is to evaluate whether macitentan 10 mg reduces N-terminal pro-brain natriuretic peptide (NT-pro-BNP) as compared to placebo in these patients.

Clinical Study Identifier: NCT03153111

Contact Investigators or Research Sites near you

Start Over

Cedars Sinai Heart Institute

Beverly Hills, CA United States
  Connect »

Weill Cornell Medicine

New York, NY United States
  Connect »

Lehigh Valley Health Network

Allentown, PA United States
  Connect »

AnMed Health

Anderson, SC United States
  Connect »

Baylor Scott & White

Temple, TX United States
  Connect »

Inova Heart and Vascular Institute

Falls Church, VA United States
  Connect »

Sharp Memorial Hospital

San Diego, CA United States
  Connect »

University of Maryland

Baltimore, MD United States
  Connect »

Peak Clinical Trials

Apex, NC United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.